Introduction

Mavacamten is the first-in-class, cardiac-specific myosin inhibitor that targets myosin, a protein central to the pathophysiology of obstructive hypertrophic cardiomyopathy (HCM). By reversibly binding to myosin molecules (myosin ATPase), Mavacamten reduces the hypercontractile state of the cardiac muscle by lowering the probability of myosin being in an active state and thereby mitigating associated adverse metabolic effects^1,2 .  The United State Food and Drug Administration (FDA) approved Mavacamten in April 2022, following results from the pivotal EXPLORER-HCM trial.¹⁰